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SARS-CoV-2 is the novel coronavirus responsible for the current COVID-19 pandemic.
Severe complications are observed only in a small proportion of infected patients but the
cellular mechanisms underlying this progression are still unknown. Comprehensive flow
cytometry of whole blood samples from 54 COVID-19 patients reveals a dramatic increase in
the number of immature neutrophils. This increase strongly correlates with disease severity
and is associated with elevated IL-6 and IP-10 levels, two key players in the cytokine storm.
The most pronounced decrease in cell counts is observed for CD8 T-cells and VD2 γδ T-cells,
which both exhibit increased differentiation and activation. ROC analysis reveals that the
count ratio of immature neutrophils to VD2 (or CD8) T-cells predicts pneumonia onset
(0.9071) as well as hypoxia onset (0.8908) with high sensitivity and specificity. It would thus
be a useful prognostic marker for preventive patient management and improved healthcare
resource management.
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Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) first appeared in Wuhan, China in late 2019. It is anovel pathogen responsible for the coronavirus disease 2019
(COVID-19) pandemic1. COVID-19 patients experience a wide
spectrum of clinical manifestations that ranges from low-grade
fever and mild respiratory symptoms, to more severe forms. This
includes acute respiratory distress syndrome (ARDS), which
requires provision of supplemental oxygen, and in some cases
intubation and mechanical ventilation2–5. The majority of critical
cases of COVID-19 are associated with coagulopathy with a high
prevalence of thromboembolic events in patients under
mechanical ventilation which lead to inclusion of anticoagulation
therapies in the standard of care of severe COVID-19 cases6–8.
While the strong inflammatory response to COVID-19 is pro-
posed to be associated to COVID-19 associated coagulopathy6, it
remains unclear how SARS-CoV-2 infection affects the activation
of immune cells and their contribution towards the severity of
disease outcomes in patients.
Previous clinical studies reported associations with clinical
blood counts, while others specifically assessed T-cell subsets for
activation and exhaustion markers9–11. Since strong evidence
points to a cytokine storm as the culprit for disease severity12,13,
various groups have investigated cytokine-secreting pathogenic
T-cells and inflammatory monocytes that could have triggered
this phenomenon9–11. In addition, flow cytometry analysis in
COVID-19 patients has also shown a polarisation towards the
Th17 subtype and a highly activated and exhausted CD8+ T-cell
compartment14,15. All these studies were carried out on periph-
eral blood mononuclear cells (PBMCs), thus excluding most
granulocyte populations14,15. However, to elucidate all the
immune subsets that could potentially trigger severe COVID-19
pathology, it is imperative to perform comprehensive whole blood
immunophenotyping of COVID-19 patients which includes
granulocyte populations.
In this study, we employ high dimensional flow cytometry to
analyse a wide spectrum of more than 50 subsets of the myeloid
and lymphoid immune cell compartments. The study focuses on
a cohort of 54 COVID-19 patients who presented with varied
clinical manifestations ranging from mild to fatal outcomes
during the ongoing SARS-CoV-2 pandemic in Singapore. This
comprehensive immunophenotyping identifies immature neu-
trophils, CD8 T-cells and gamma delta (VD) 2 T-cells as key
immune cell populations that undergo substantial changes in the
cell counts across the spectrum of clinical severity. Their num-
bers, in fact, represent an early and robust prognosis value as
shown by receiver operating characteristics (ROC) analysis.
Results
Circulating myeloid cells are decreased in COVID-19 patients.
A total of 54 patients with laboratory-confirmed SARS-CoV-2
infection were recruited at the National Centre for Infectious
Diseases (NCID), Singapore from end March to mid-May 2020
(Supplementary Table 1). Blood was collected from 54 patients
upon enrolment at a median 7 days post-illness onset (pio)
(Supplementary Table 1), from 28 patients who had recovered
from COVID-19 disease (median 30 days pio) (Supplementary
Table 1) and 19 healthy donors (Supplementary Table 2).
Unfortunately, only 11 patients had paired acquisition between
acute and recovered which prevented meaningful paired analysis
(Supplementary Table 1). Immunophenotyping of whole blood
samples was carried out with three distinct flow cytometry panels
to analyse myeloid, granulocyte and lymphoid subsets. (Fig. 1a,
Supplementary Table 3). Each panel was supplemented with
counting beads to allow accurate assessment of cell counts. 19 of
the 54 acute patients had paired plasma samples that permitted
quantification of immune mediators by Luminex multiplex
microbead-based immunoassay. The cohort was strongly biased
towards males, of which three patients experienced a throm-
boembolism event (5.6%) and two patients had fatal outcomes
(3.7%).
First, we assessed using healthy donor samples, if the different
blood collection method for recovered samples affected cell
counts or activation markers. We observed that, while the cell
count was not affected, expression of activation markers was
affected on most cells but not CD38+ on T-cells (Supplemental
Fig. 1a), allowing direct comparison of activation markers only
between healthy and acute samples. The FACS analysis revealed a
declined cell count for eosinophils, basophils, total T-cells,
dendritic cells (DCs), natural killer (NK) CD56 Bright, and
plasmacitoid DCs (pDCs) in patients with acute COVID-19
infection (Fig. 1b, Supplementary Fig. 1a). No significant changes
were observed for B-cells, total monocytes, and total NK cells
(Fig. 1b, Supplementary Fig. 1a). Unbiased analysis by Uniform
Manifold Approximation and Projection (UMAP) and graph-
based clustering however identified with CD169+ monocytes and
CD11bhigh neutrophils, two additional clusters with high
variation in acute patients (Fig. 1c). Further analysis showed
that the monocytes presented with an increased expression of
CD169 (strong type I interferon signature marker16), increased
expression of CD11b and HLA-DR, as well as CD33, a
constitutive PI3K signalling inhibitor17,18 (Fig. 1d, Supplementary
Fig. 1b) as compared to healthy donors.
Similar to the monocytes, neutrophils showed a significant
upregulation of CD11b, CD66b, Siglec 8, CD38 and HLA-DR,
suggesting that they were activated in response to SARS-CoV-2
infection (Fig. 1e, Supplementary Fig. 1c). Interestingly, despite
this activation phenotype, an increase in the overall number of
circulating neutrophils during acute SARS-CoV-2 infection
based on conventional phenotypic markers (CD66b, CD11b
and CD16) was observed only in a small subset of our cohort
(Fig. 1f). However, in-depth analysis of neutrophil subsets
allows discrimination between immature (CD16low/highCD10−)
and mature (CD16highCD10+) subsets (Fig. 1g)19–21. Overall, a
significant increase of immature neutrophil numbers was
observed in acute patients as compared to healthy donors or
recovered patients, while the number of mature neutrophils
decreased (Fig. 1h).
CD8 and γδ T-cells are the most affected lymphocyte subsets.
To better characterise COVID-19-induced lymphopenia, levels of
CD8, CD4, γδ (i.e., VD1 and VD2), and mucosal-associated
invariant T-cells (MAIT, CD3+VA7.2+CD161+) were assessed
during acute infection. Results showed a decrease in circulating
MAIT, CD8+ and VD2 T-cells (Fig. 2a). However, circulating
VD1 T-cells did not vary in numbers, and CD4+ T-cells did not
show a significant decrease during acute infection (Fig. 2a).
Interestingly, levels of regulatory T-cells (Treg) and CD4+
CD161+ T-cells increased in recovered patients as compared to
acute patients (Fig. 2a).
Next, UMAP analysis was done on CD3+ cells to visualise
changes in differentiation states within the T-cell compartments
(Fig. 2b). UMAP visualisation suggests that phenotypic modula-
tion in the CD8+ cluster was the most pronounced during SARS-
CoV-2 infection (Fig. 2b). In order to validate this observation,
CD45RA and CD27 markers were used to analyse the frequency
of naïve (CD45RA+CD27+), central memory (CM, CD45RA−
CD27+), effector memory (EM, CD45RA−CD27−) and terminal
effector (TEMRA, CD45RA+CD27−) amongst the T-cell popula-
tions (Fig. 2c, Supplementary Fig. 2). In agreement with the
UMAP analysis, CD8+ T-cells showed a change in differentiation
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profile from naïve in favour of EM and TEMRA (Fig. 2c).
Noticeably, the frequency of naïve CD4+ T-cells decreased but
was not reflected in a significant increase of a specific
differentiated population (Fig. 2c).
In addition, UMAP analysis also suggested changes in VD1
and VD2 populations that were not reflected in terms of
differentiation (Fig. 2b, c). Therefore, we investigated the
expression of general activation marker CD38. In this context,
we observed that all differentiation stages of CD8+ T-cells,
VD1 and VD2, had higher expression of CD38 except VD2
TEMRA (Fig. 2d). On the other hand, CD4+ T-cells did not
show difference in the CD38 activation marker expression
Lyse RBCs





















































































Healthy donors COVID-19 Acute COVID-19 Recovered
























































































Monocytes activation markers gMFI
Healthy
Acute








Neutrophils activation markers gMFI
Healthy
Acute
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19080-6 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5243 | https://doi.org/10.1038/s41467-020-19080-6 | www.nature.com/naturecommunications 3
(Fig. 2d). Together, our data suggest that while circulating cell
counts were generally decreased for T-cells, SARS-CoV-2
differentially impacts the different T-cell subsets in terms cell
counts, differentiation and expression of CD38.
Clinical severity is reflected by immune cell counts. In order to
associate the data with the clinical severity we separated the
patients into four different groups: no pneumonia, pneumonia
only, pneumonia and hypoxia, and pneumonia and hypoxia
requiring ICU admission (Fig. 3a)22,23. This allowed estimation of
cell counts in those groups and identification of markers that
potentially depict disease severity. Consistent with previous stu-
dies on CD4 and CD8 lymphopenia9,24,25, CD8+, CD4+, MAIT,
VD1 and VD2 T-cells showed a gradual reduction in the per-
ipheral blood with increasing disease severity (Fig. 3b). The effect
was more pronounced for CD8+ and VD2 T-cells (Fig. 3b),
suggesting a strong activation and infiltration of these cells in the
lungs.
Cell counts in various myeloid subsets showed a similar
decreasing profile with severity for pDCs, DCs, classical and
intermediate monocytes (Fig. 3c). In contrast to cell counts,
myeloid activation markers showed differential trends with
severity (Fig. 3d). CD86 expression on DCs, HLA-DR and
CD33 expression on monocytes followed a gradual decrease with
increasing severity (Fig. 3d). Expression of CD169 on monocytes
was decreased in ICU patients, while CD86 expression on pDCs
was consistent across severity groups (Fig. 3d). Together, these
results suggest that the remaining circulating monocytes and DCs
in severe cases have a dysregulated phenotype.
While total circulating neutrophils showed no significant
change with disease severity, neutrophilia was only observed in
some patients with severe clinical complications (Fig. 3e).
Particularly, there was a change in the composition of neutrophil
subsets in accordance to disease severity, where an increase in the
immature neutrophil cell count and frequency was accompanied
with a decrease of mature neutrophils (Fig. 3e). These results
suggest that immature neutrophils could reflect disease severity
much more accurately than total neutrophil counts.
Immature neutrophil absolute count correlates with cytokines.
Neutrophil-to-Lymphocyte Ratio (NLR) or Neutrophil-to-CD8
T-cell Ratio (N8R) were proposed to be good diagnostic and
prognostic markers for severe COVID-19 respiratory disease25,26.
However, these studies observed increased neutrophils in severe
cases which was not consistent with our observations and in
another study27 (Figs. 1g and 3e). To validate that the identified
populations would be good markers of disease severity, a corre-
lation analysis between analyte levels in available paired plasma
samples (from CPT sodium citrate tubes) was performed with the
cell counts obtained in FACS (from EDTA vacuette tubes)
(Fig. 4a, Supplementary Fig. 3). Interestingly, strong correlation
scores were observed between analytes and immature neutrophil
counts (Fig. 4a, Supplementary Fig. 3a), rather than with total
neutrophil counts (Fig. 4a, Supplementary Fig. 3b). The strongest
correlations were observed between immature neutrophil counts
and IL-6 (rho= 0.6747, p= 0.0015), and IP-10 (rho= 0.7596,
p= 0.0002) (Fig. 4b).
In addition, strong correlations were also observed between
mature neutrophils, monocytes and intermediate monocytes, as
well as CD8 and VD2 T-cell counts (Supplementary Fig. 3c).
These results suggest that immature neutrophils counts can
potentially be used as sensitive and reliable indicators of disease
severity.
Immature neutrophil/VD2 ratio an improved prognostic
marker. We next assessed if an immature neutrophil-to-CD8 T-
cells ratio (iN8R) or VD2 T-cell counts ratio (iNVD2R) could be
a better prognostic marker of disease severity as compared to the
current proposed NLR and N8R25,26. To differentiate patients
with and without pneumonia, iNVD2R performed better than
N8R or iN8R with an area under receiver operating characteristic
(AUROC) curve of 0.8451 (95% confidence interval CI:
0.7379–0.9523) vs 0.806 (95% CI: 0.6911–0.9210) and 0.7158
(95% CI: 0.5754–0.8562) respectively (Fig. 5a). In addition, to
differentiate patients with and without hypoxia, an AUROC of
0.9111 (95% CI: 0.8306–0.9916) was obtained for iNVD2R as
compared to 0.8931 (95% CI: 0.8044–0.9817) for iN8R and 0.7958
(95% CI: 0.6781–0.9136) for N8R. These results indicate that
iNVD2R and iN8R could be good markers for severe respiratory
disease.
To assess if this analysis could have predictive prognostic value
in hospitalisation settings to improve patient management, we
repeated the same analysis with only samples that were acquired
at or before 7 days pio amongst the 54 acute patients (24 patients,
median pio = 3 days, range 1 to 7 days pio). AUROC for
iNVD2R showed strong prognostic value for pneumonia onset
(0.9071) as well as for onset of hypoxia (0.8908) (Fig. 5b, Table 1).
Our data show that immature neutrophil counts are better in
predicting disease severity as compared to total neutrophil counts.
Importantly, they can be used in a ratio with CD8 or VD2
lymphocyte counts to improve the current N8R predictive ratio.
Discussion
In this study, immunophenotyping of peripheral blood from
COVID-19 patients revealed a significant shift in the ratio
between mature and immature neutrophils associating with
severity. The increased numbers of immature neutrophils and the
disappearance of mature neutrophils likely reflect gradual and
sustained mobilisation of these cells into the lungs in response to
an ongoing inflammation, leading to premature release of
immature neutrophils from the bone marrow21. Supporting this
hypothesis, a recent study, investigating several myeloid popula-
tions between circulating PBMCs and the lung lavage of COVID-
19 patients showed that granulocytes represent up to 80% of total
Fig. 1 SARS-CoV-2 infection induces a decrease in immune cells in peripheral blood. a Schematic representation of flow cytometry workflow. b Heatmap
representation of row z-score of mean absolute cell counts across the groups. Individual plots are shown in Supplementary Fig. 1A. c UMAP clustering of
CD45+ immune cells. d Monocyte activation markers mean geometric MFI (gMFI). e Neutrophil activation markers mean geometric MFI (gMFI).
f Absolute neutrophil counts. g Representative plot of mature and immature neutrophil gating strategy in healthy control or acute COVID-19 patient.
h Mature (CD10+) and immature (CD10−) neutrophil Abs counts. Data presented are from individual human samples of healthy n= 17, acute n= 54 and
recovered n= 26 common in flow panels a and c. Heatmap is presented as mean of z-score, scatter dot plots are presented with mean ± SD. Absolute
counts were analysed by Kruskal–Wallis using Dunn correction for multiple comparison, gMFI was analysed by Brown-Forsythe and Welch ANOVA
without multiple comparison. For heatmap, stars shown in acute column represent healthy vs acute comparison. Stars shown in recovered column
represent acute vs recovered comparison. ns non-significant. *p < 0.05, **p < 0.01, ***p < 0.001. Data available in source data file, exact p-values are given
in Supplementary Data 1.
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CD45+ lung infiltrates28. In addition, autopsies of COVID-19
fatalities showed typical lesions associated with toxic neutrophil
effects29,30. In line with this observation, marked morphological
abnormalities of the circulating neutrophils were reported in
COVID-19 patients27. These cells present typical hallmarks of
immature neutrophils and their precursors such as band shaped
nuclei and a lower expression of CD10 and CD1631. Consistent
with our data, a recent non peer reviewed study on a small
number of patients reported that the presence of low density
inflammatory neutrophils was strongly associated with disease
severity and IL-6 levels32. Functionally these low density neu-
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enhanced cytokine production and associated with D-dimer and
systemic IL-6 and TNF-α levels32. We hypothesise that the
CD11bintCD44lowCD16int low density neutrophil population
indentified in that study is likely constituted primarily of CD10−
immature neutrophils. More recently, two studies used flow
cytometry, single cell sequencing and mass cytometry to confirm
the immature and dysfunctional phenotype in the myeloid
populations, including these neutrophils33,34. Interestingly, the
diagnostic value of a neutrophil left shift (banded versus seg-
mented neutrophils) had previously been explored in order to
predict infectious diseases in addition to inflammatory diseases35
and is therefore not limited to COVID-19 severity. Similarly, the
presence of immature low density neutrophils have been reported
in the literature for various infectious and inflammatory dis-
eases36–38 as well as induced by LPS in healthy subjects39, high-
lighting the necessity of future studies to compare the role and
function of these COVID-19 immature neutrophils with the
circulating immature neutrophils present in other diseases.
During SARS-CoV-2 infection, immature neutrophil numbers
strongly correlated with IL-6 and IP-10. IL-6 and IP-10 are
consistently upregulated during a cytokine storm and are asso-
ciated with severe ARDS9,12,40,41. While some studies report
inflammatory monocytes as the source of IL-69,42,43, our results
suggest that immature neutrophils could also be a non-negligible
source of IL-6 during COVID-19-induced cytokine storm.
Indeed, neutrophils have been found to produce biologically
relevant amounts of IL-6 after engagement of TLR8, a toll like
receptor recognising single strand RNAs of viral or bacterial
origin44,45. Since IL-17 operates upstream of IL-1 and IL-6, and is
a major orchestrator of sustained neutrophils mobilisation46, it is
plausible that IL-17 could significantly affect the neutrophils
compartment in COVID-19 patients. Consistent with this
hypothesis, CD4 T-cells in COVID-19 patients are skewed
towards a Th17 phenotype15, and we also observed increased
CD4+CD161+ T-cells in recovered patients. These CD4+CD161
+ T-cells are known to be either IL-17 producer cells or their
precursors47. Thus, our results could reflect the re-circulation of
these cells from the lung or secondary lymphoid organs after
infection and support the possibility of IL-17 in mediating neu-
trophil damage to the lungs. Together, this would support pro-
posed anti-IL-17 or JAK2 inhibitor therapies for severe COVID-
19 disease48–50.
In addition to the changes in the heterogeneity of neutrophils,
a strong decrease in T-cells was observed, especially in subsets
that possess cytolytic activity such as CD8, VD1 and VD2 T-cells.
These results are consistent with other studies showing a decrease
of CD8+ during COVID-19 disease14,15. As for VD2 T-cells,
which are not MHC-restricted T-cells51,52, we showed a general
decrease in the periphery with disease severity. This is in line with
other inflammatory disease such as psoriasis53 and Crohn’s dis-
ease54. However, in the lungs, during chronic obstructive pul-
monary disease, γδ T-cell counts have been reported to be
significantly lower in induced sputum (IS) and bronchoalveolar
lavage (BAL) but not in peripheral blood, suggesting unclear
inflammatory mechanisms that could influence γδ T-cells counts
in the periphery55. Interestingly, γδ T-cells, in particular VD2, are
known to participate in influenza immune response56, and
actively recruit and activate neutrophils to the site of infection or
inflammation57,58. Activated, neutrophils have also been found to
inhibit γδ T-cells functional capacity, promoting the resolution of
inflammation59,60. Therefore, it will be essential to investigate the
neutrophil to γδ T-cells relashionship present in lungs of SARS-
CoV-2 infected patients.
During aging, VD2 T-cell counts in the periphery have been
shown to decrease with age for both males and females61–64.
Interestingly, VD2 counts between males and females can be
quite variable depending on the population sampled. Higher VD2
counts in males were observed in a Japanese population, while a
similar study in Germany and Italy observed higher VD2 counts
in females61,64. Additionally, elderly individuals generally have
systemic chronic low-grade inflammation, which was previously
termed as inflamm-aging65, with higher basal levels of molecules
such as CRP, TNF-a and IL-666–68. These similarities in mod-
ulation of VD2 T-cell counts and cytokines between COVID-19
severity and aging could explain why elderly individuals are more
susceptible to severe disease, since they have a higher basal level
of inflammation and lower level of VD2 T-cells as compared to
the young. In any case, the lower VD2 counts in elderly popu-
lations will influence the immature neutrophil to VD2 ratio by
overestimating their risk to severe COVID-19 as compared to a
younger population. However, since age is a very well established
risk factor for severe COVID-19 disease69–71, we postulate that
the immature neutrophil to VD2 ratio takes into account the
immunological age (measured by VD2 T-cell counts of the
patient) which contributes to the improved sensitivity and spe-
cificity observed here with area under receiver operating char-
acteristic analysis (Fig. 5).
Our results indicate that an early post illness onset iNVD2R,
accessible through a simple 6 colours flow cytometry panel (CD3;
VD2; CD66b/CD15; CD16; CD10; CD45), would be an excellent
prognostic screening tool for predicting probable patient pro-
gression to pneumonia or hypoxia. This prognostic possibility
needs to be validated in a prospective cohort. Moreover, CD8
could also be included in the flow cytometry panel as a fallback
option since VD2 counts could be decreased by medication, such
as Azathioprine, as well as underlying conditions, such as
inflammatory bowel disease, aging or psoriasis, which could be
risk factors for COVID-1954. Analysis of the proposed parameter
would allow for a more accurate and earlier prognosis due to the
interconnection between neutrophils and Vδ2 T cells, which can
then be utilised for early therapeutic interventions, improve
patient triage and better healthcare resource management.
Methods
Study design. This was an observational cohort study of patients with PCR-
confirmed COVID-19 who were admitted to the National Centre for Infectious
Diseases, Singapore. All patients with COVID-19 in Singapore, regardless of the
severity of infection, are admitted to isolation facilities until clinical recovery and
Fig. 2 SARS-CoV-2 infection induces general lymphopenia and CD8, VD1 and VD2 activation. a Absolute counts of T-cell compartments in healthy
donors, acute and recovered COVID-19 patient. b UMAP clustering of CD3+ cells. c left panel: CD45RA and CD27 gating strategy example on CD8+ T-
cells; right panel: heatmap representation of mean frequencies of T-cell differentiation across the groups, individual plots given in Supplementary Fig. 2.
d Changes in CD38 gMFI in naïve, CM, EM and TEMRA for CD8, CD4, VD1 and VD2 T-cells. ND indicates not determined since frequency of these
compartment was too low for accurate gMFI measurement. Data presented are from individual human samples of healthy n= 19, acute n= 54 and
recovered n= 28 from flow panel B. Absolute counts and frequency were analysed by Kruskal–Wallis using Dunn correction for multiple comparison, gMFI
was analysed by Brown–Forsythe and Welch ANOVA using Dunnett T3 correction for multiple comparison. Scatter dot plots are presented as mean ± SD.
For heatmaps, stars shown in acute column represent healthy vs acute comparison. Stars shown in recovered column represent acute vs recovered
comparison. *p < 0.05, **p < 0.01, ***p < 0.001. Data available in source data file, exact p-values are given in Supplementary Data 1.
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viral clearance. Supportive therapy including supplemental oxygen and sympto-
matic treatment were administered as required. Pneumonia was diagnosed radi-
ologically by interpretation of CXR or CT thorax images. Hypoxia is defined as
requirement for supplemental oxygen, which was started if peripheral O2 satura-
tions (SpO2) were <94%. Admission to ICU was reserved for those patients
requiring [FiO2] ≥40% or with haemodynamic instability, and included invasive
mechanical ventilation when necessary. Incidence of thrombo-embolic and cardiac
events are indicated in Supplemental Table 1.
Sample Size: No power analysis was done. Sample size was based on sample
availability. Randomisation: No randomisation was done. Blinding: Clinical
parameters were made available after data analysis. Patient clinical information was
collected using Excel for Mac version 16.16.8 (Microsoft, USA).
Ethics statement. Written informed consent was obtained from participants in
accordance with the tenets of the Declaration of Helsinki. For COVID-19 blood/
No hypoxia
(n = 30)
No pneumonia (n = 19)
Pneumonia (n = 11)
Pneumonia, hypoxia (n = 9)
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Fig. 3 Patient symptoms are reflected in immune cell variations. a Schematic representation of clinical symptoms in the patient cohort. b Absolute counts
of T-cells across the severity. c Absolute counts of antigen presenting cells across the severity. d gMFI of activation markers on antigen presenting cells.
e Absolute counts and frequency in neutrophil compartments. Data presented are from individual human acute COVID-19 patients n= 54 from panels
a, b and c, separated according to clinical severity: no pneumonia n= 19, pneumonia no hypoxia n= 11, pneumonia with hypoxia no ICU n= 9, pneumonia
with hypoxia with ICU n= 15. Scatter dot plots are presented with mean ± SD. Absolute counts and frequency were analysed by Kruskal–Wallis with Dunn
multiple testing correction, gMFI was analysed by Brown–Forsythe and Welch ANOVA with Dunnett T3 multiple testing correction. *p < 0.05, **p < 0.01,
***p < 0.001. Data available in source data file, exact p-values are given in Supplementary Data 1.
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plasma collection, “A Multi-centred Prospective Study to Detect Novel Pathogens
and Characterize Emerging Infections (The PROTECT study group)”, a domain
specific review board (DSRB) evaluated the study design and protocol, which was
approved under study number 2012/00917 the National Healthcare Group (NHG).
Healthy volunteers samples were obtained under the following IRB “Study of blood
cell subsets and their products in models of infection, inflammation and immune
regulation” under the number 2017/2806 by the SingHealth Centralised Institu-
tional Review Board (CIRB).
Donor information. Patients who tested PCR-positive for SARS-CoV-2 in a
respiratory sample from February to April 2020 were recruited into the study72.
Demographic data, days post disease onset date (unavailable for 5 asymptomatic
patients), clinical score and SARS-CoV-2 RT-PCR results during the hospitalisa-
tion period were retrieved from patient clinical records. Relevant information are
given in Supplementary Table 1. Patients were classified in different clinical severity
groups depending on the presence of pneumonia, hypoxia and the need for ICU
hospitalisation. For healthy volunteers, demographic data are provided in Sup-
plementary Table 2. Blood was collected in VACUETTE EDTA tubes (Greiner Bio,
#455036) for healthy donors and acute patients, or Cell Preparation Tubes (CPT)
(BD, #362761) for recovered patients. 100 μL of whole blood was extracted for each
FACS staining panel (Supplementary Table 3).
Multiplex microbead-based immunoassay. When available, plasma fraction was
harvested after 20 min centrifugation at 1700 x g of blood collected in BD Vacu-
tainer CPT tubes (BD, #362761). Plasma samples were treated by solvent/detergent
treatment with a final concentration of 1% (volume) Triton X-100 (Thermo Fisher
Scientific, #28314) for virus inactivation at RT for 2 h in the dark under stringent
Biosafety laboratory 2+ conditions (approved by Singapore Ministry of Health)73.
Cytokines detection in Triton-X treatment was compared with untreated samples
for healthy donor and was found to be highly correlative for detected cytokines
except for sCD40 (Supplemental Fig. 7). Immune mediator levels in COVID-19
patient plasma samples across acute samples were measured with by Luminex
using the Cytokine/Chemokine/Growth Factor 45-plex Human ProcartaPlexTM
Panel 1 (ThermoFisher Scientific, #EPX450-12171-901). Data acquisition was
performed on FLEXMAP® 3D (Luminex) using xPONENT® 4.0 (Luminex) soft-
ware. Data analysis was done on Bio-Plex ManagerTM 6.1.1 (Bio-Rad). Standard
curves were generated with a 5-PL (5-parameter logistic) algorithm, reporting
values for both mean florescence intensity (MFI) and concentration data. Luminex
data was generated from four different runs with each run having a number of
samples which are common to the first run. For each subsequent run beyond the
first, the mean of the common samples on each of the plates for each analyte was
compared to the mean of the same samples in the first run to obtain a correction
factor expressed in the following formula:
correction_factor = mean(common_sample_concentration_in_run1)—mean
(common_sample_concentration_in_subsequent_run). This correction factor was
computed for each plate and analyte combination in the subsequent runs and
added to the observed concentration to get the final normalised concentration. In
the event that none of the common samples had concentration within the standard
curve, no correction was done. Analyte concentrations were logarithmically
transformed to ensure normality. Analytes that were not detectable in patient
samples were assigned the value of logarithmic transformation of Limit of
Quantification (LOQ).
Flow cytometry. Whole blood was stained with antibodies as stated in Supple-
mentary Table 3 (100 μL of whole blood per flow cytometry panel) for 20 min in
the dark at RT. Samples were then supplemented with 0.5 mL of 1.2× BD FACS
lysing solution (BD 349202). Final FACS lysing solution concentration taking into
account volume in tube before addition is 1×. Samples were vortexed and incu-
bated for 10 min at RT. 500 μL of PBS (Gibco, #10010-031) was added to wash the
samples and centrifugated at 300 g for 5 min. Washing step of samples were
repeated with 1 mL of PBS. Samples were then transferred to polystyrene FACS
tubes containing 10 μL (10800 beads) of CountBright Absolute Counting Beads
(Invitrogen, #36950). Samples were then acquired without delay, with vortexing
before and every 3 min during acquisition to minimise fixed cell adherence to the
tubes, using BD LSRII 5 laser configuration using automatic compensations and
running BD FACS Diva Software version 8.0.1 (build 2014 07 03 11 47), Firmware
version 1.14 (BDLSR II), CST version 3.0.1, PLA version 2.0. Analysis of flow
cytometric data was performed with FlowJo version 10.6.1. Gating strategies for
panels A, B and C are presented in Supplementary Figs. 4–6, respectively. LSRII
image in Fig. 1a was created with BioRender.com, and person silhouettes were
modified from public domain art (clipartkey.com).
Statistical analysis. Statistical analysis was performed using Prism 7.03 to 8.3.0
(Graph Pad Software, Inc). For comparisons of absolute cell counts or frequency,
Kruskal-Wallis Test corrected with Dunn’s method was performed. For compar-
isons of geometric Mean Fluorescence Intensity (gMFI) between three or more
independent groups, Brown-Forsythe and Welch ANOVA using Dunnett T3
correction for multiple comparison was performed. For comparisons of geometric
Mean Fluorescence Intensity (gMFI) between two independent groups, Brown-
Forsythe and Welch ANOVA without correction for multiple comparison was
performed. For correlation analysis, spearman rank correlation was performed. p-
Values < 0.05 for correlations, while adjusted p-values <0.05 for all the other















































































































Fig. 4 Immature neutrophils correlate with several analytes in paired patient plasma. a Spearman correlations between total neutrophils or immature
neutrophils and plasma analytes. Red cross represents non-significant correlations. b Individual plots of Spearman correlations between immature
neutrophil counts and IL-6 and IP-10. Line was drawn using simple linear regression. Data was analysed using non-parametric Spearman correlation two-
tailed function in Prism. Data from n= 19 individual acute COVID-19 patients. Data available in source data file.
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Fig. 5 Immature neutrophil to VD2 T-cell ratio is an early prognosis marker for pneumonia and hypoxia symptoms. a ROC curve analysis comparison
was performed for pneumonia and hypoxia symptoms between absolute counts of total neutrophils to CD8 T-cell ratio, total neutrophils to VD2 T-cell,
immature neutrophils to CD8 T-cell ratio, and immature neutrophils to VD2 T-cell ratio, n= 54 individual acute COVID-19 patient samples. b Similar
analysis was performed on a subset of early samples from the 54 acute patients (n= 24 individual acute COVID-19 patients following the criteria: sampled
at 1 to 7 days pio. Median of this subset is 3 days pio). ROC curve was analysed using Wilson/Brown method, 95% confidence interval and standard error
for panel A are given in Supplementary Data 1 and for panel B are given in Table 1. Data available in source data file.
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Data analysis and UMAP visualisation. UMAP: Gated cells were manually
exported using FlowJo (Tree Star Inc.). Samples were then used for UMAP analysis
using cytofkit2 R Packages with RStudio v3.5.274. Five healthy, six acute and four
recovered patients were each concatenated to its respective groups and 100000 cells
were analysed using the ceil method. Custom R scripts were used to generate Z-
score and correlation heatmaps.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Custom R scripts are available in Supplementary Software 1. Other data not made
publicly available due to protection of patients’ confidentiality can be obtained upon
request to the corresponding author. Source data are provided with this paper.
Received: 4 June 2020; Accepted: 22 September 2020;
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